Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn’s disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months. In a large study published in Alimentary Pharmacology and Therapeutics, researchers at 19 centres in the UK report that, among 2,385 patients with inflammatory bowel disease, 14.8% showed evidence of steroid excess or dependency, and the steroid excess was judged avoidable in over 50% of cases.
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn’s disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months. In a large study published in Alimentary Pharmacology and Therapeutics, researchers at 19 centres in the UK report that, among 2,385 patients with inflammatory bowel disease, 14.8% showed evidence of steroid excess or dependency, and the steroid excess was judged avoidable in over 50% of cases.
The seven centres that had participated in a quality improvement programme had significantly fewer patients (11.5% versus 17.1%) receiving excess steroids.
“Looking at steroid prescribing for inflammatory bowel disease and trying to reduce steroid excess can be a powerful way to improve patient care and outcomes,” said lead author Christian P. Selinger, MD, MSc, MRCP, of St. James University Hospital.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/apt.15497
About Journal
Alimentary Pharmacology & Therapeutics is an international journal of gastroenterology and hepatology.
The journal accepts systematic reviews, meta-analyses, randomised controlled trials and original papers concerned with Gastroenterology and Hepatology.
AP&T is particularly interested in therapies and diagnostics, including all aspects of translation from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety and meta-analyses.
About Wiley
Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.
Penny Smith +44 (0) 1243 770448 (UK)
newsroom@wiley.com